Patrick J. Haley serves as Executive Vice President, Commercial at Exelixis, Inc., a leading biopharmaceutical company focused on oncology therapeutics. In this pivotal role, he oversees the company's global commercial strategy, including sales, marketing, market access, and trade operations. Haley drives the commercialization of Exelixis' flagship products, such as CABOMETYX® (cabozantinib) and COMETRIQ® (cabozantinib), ensuring robust market penetration and growth in competitive oncology landscapes. With over 25 years of experience in the pharmaceutical industry, Haley joined Exelixis in 2018 from Genentech, a member of the Roche Group, where he held senior leadership positions, most recently as Senior Vice President, U.S. Oncology. His earlier career included progressive roles in commercial operations, marketing, and sales at Bristol-Myers Squibb and Pfizer, where he honed expertise in launching blockbuster oncology products and building high-performing commercial teams. Under Haley's leadership, Exelixis has achieved significant commercial milestones, including expanding CABOMETYX into frontline renal cell carcinoma and hepatocellular carcinoma indications, resulting in substantial revenue growth and market share gains. His strategic acumen has been instrumental in positioning Exelixis as a key player in precision oncology, fostering innovation in commercial execution and payer partnerships.